ADMA Biologics: RSI Oversold and KDJ Golden Cross on 15-Minute Chart

Based on ADMA Biologics's 15-minute chart, recent technical indicators have triggered a "RSI Oversold" signal and a "KDJ Golden Cross" at 09/29/2025 15:30. This suggests that the stock's price has declined rapidly, potentially falling below its fundamental support levels. Additionally, the momentum of the stock's price is shifting towards an upward trajectory, indicating a potential for further growth.

Adma Biologics (ADMA), a company specializing in infectious disease drug development, experienced a significant decline in its stock price, closing at $15.32 on September 12, 2025, down by 2.17% from the previous session. This performance lagged behind the broader market indices, with the S&P 500 losing 0.5%, the Dow dropping 0.38%, and the tech-heavy Nasdaq losing 0.5% Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Over the past month, ADMA's stock has depreciated by 9.22%, underperforming the Medical sector's loss of 0.7% and the S&P 500's gain of 2.74% Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1]. Despite this decline, analysts and investors are closely monitoring the company's upcoming earnings report, expected to be released soon. The consensus estimate predicts an earnings per share (EPS) of $0.16, indicating a 6.67% growth compared to the same period last year. Quarterly revenue is forecasted to reach $130.1 million, marking an 8.56% increase from the previous year Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

ADMA's full-year Zacks Consensus Estimates project earnings of $0.57 per share and revenue of $506.7 million, representing year-over-year changes of +16.33% and +18.82%, respectively Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1]. These estimates suggest a positive outlook for the company's financial performance. Investors should also note recent changes in analyst estimates, which reflect the evolving business trends and indicate a favorable outlook on the company's profitability Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Technical indicators provide additional insights into ADMA's stock performance. Recent analysis of the 15-minute chart shows an "RSI Oversold" signal and a "KDJ Golden Cross" at 09/29/2025 15:30. These signals suggest that the stock's price has declined rapidly, potentially falling below its fundamental support levels. However, the momentum of the stock's price is shifting towards an upward trajectory, indicating a potential for further growth Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[2].

ADMA's current valuation metrics also warrant attention. The company's Forward P/E ratio stands at 27.47, which is higher than the industry average Forward P/E of 19.43. This premium valuation reflects the market's expectations for the company's future performance Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

The Medical - Biomedical and Genetics industry, to which ADMA belongs, is part of the Medical sector. This group has a Zacks Industry Rank of 88, placing it in the top 36% of all 250+ industries. The Zacks Industry Rank assesses the vigor of specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in them Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Investors should keep an eye on ADMA's upcoming earnings report and the evolving technical indicators to make informed investment decisions. For the latest stock-moving metrics and industry insights, visit Zacks.com Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].